<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>00840140737479</udiDi>
    <basicUdiDi>B-00840140737479</basicUdiDi>
    <tradeName>TSH</tradeName>
    <deviceName>TSH</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2608MS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:39.713Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140737462</udiDi>
    <basicUdiDi>B-00840140737462</basicUdiDi>
    <tradeName>TSH</tradeName>
    <deviceName>TSH</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2608ML</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:38.090Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140737455</udiDi>
    <basicUdiDi>B-00840140737455</basicUdiDi>
    <tradeName>Myoglobin</tradeName>
    <deviceName>Myoglobin</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2379RP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:37.425Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140737448</udiDi>
    <basicUdiDi>B-00840140737448</basicUdiDi>
    <tradeName>Myoglobin</tradeName>
    <deviceName>Myoglobin</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2379RT</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:34.885Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140737431</udiDi>
    <basicUdiDi>B-00840140737431</basicUdiDi>
    <tradeName>Myoglobin</tradeName>
    <deviceName>Myoglobin</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2379RS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:32.485Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140737424</udiDi>
    <basicUdiDi>B-00840140737424</basicUdiDi>
    <tradeName>Myoglobin</tradeName>
    <deviceName>Myoglobin</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2379RL</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:30.878Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140737417</udiDi>
    <basicUdiDi>B-00840140737417</basicUdiDi>
    <tradeName>MLH-1</tradeName>
    <deviceName>MLH-1</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2656RP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:30.084Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140737400</udiDi>
    <basicUdiDi>B-00840140737400</basicUdiDi>
    <tradeName>MLH-1</tradeName>
    <deviceName>MLH-1</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2656RT</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:28.480Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140737394</udiDi>
    <basicUdiDi>B-00840140737394</basicUdiDi>
    <tradeName>MLH-1</tradeName>
    <deviceName>MLH-1</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2656RS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:26.088Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140737387</udiDi>
    <basicUdiDi>B-00840140737387</basicUdiDi>
    <tradeName>MLH-1</tradeName>
    <deviceName>MLH-1</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2656RL</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:24.485Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140737370</udiDi>
    <basicUdiDi>B-00840140737370</basicUdiDi>
    <tradeName>ALDH1A1</tradeName>
    <deviceName>ALDH1A1</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2387ML</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:23.687Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140737240</udiDi>
    <basicUdiDi>B-00840140737240</basicUdiDi>
    <tradeName>p21WAF1</tradeName>
    <deviceName>p21WAF1</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2602RP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:23.528Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140737233</udiDi>
    <basicUdiDi>B-00840140737233</basicUdiDi>
    <tradeName>p21WAF1</tradeName>
    <deviceName>p21WAF1</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2602RT</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:18.073Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140737226</udiDi>
    <basicUdiDi>B-00840140737226</basicUdiDi>
    <tradeName>p21WAF1</tradeName>
    <deviceName>p21WAF1</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2602RS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:17.279Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140737219</udiDi>
    <basicUdiDi>B-00840140737219</basicUdiDi>
    <tradeName>p21WAF1</tradeName>
    <deviceName>p21WAF1</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2602RL</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:16.471Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140737004</udiDi>
    <basicUdiDi>B-00840140737004</basicUdiDi>
    <tradeName>Retinoblastoma (Rb)</tradeName>
    <deviceName>Retinoblastoma (Rb)</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2651MP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:15.673Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140736991</udiDi>
    <basicUdiDi>B-00840140736991</basicUdiDi>
    <tradeName>Retinoblastoma (Rb)</tradeName>
    <deviceName>Retinoblastoma (Rb)</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2651MT</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:11.673Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140736984</udiDi>
    <basicUdiDi>B-00840140736984</basicUdiDi>
    <tradeName>Retinoblastoma (Rb)</tradeName>
    <deviceName>Retinoblastoma (Rb)</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2651MS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:10.875Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140736977</udiDi>
    <basicUdiDi>B-00840140736977</basicUdiDi>
    <tradeName>Retinoblastoma (Rb)</tradeName>
    <deviceName>Retinoblastoma (Rb)</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2651ML</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:10.073Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140736649</udiDi>
    <basicUdiDi>B-00840140736649</basicUdiDi>
    <tradeName>ER</tradeName>
    <deviceName>ER</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2625MP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:56:09.280Z</lastUpdated>
  </row>
</eudamedExport>